Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

FDA And EMA Collaborate On Advice For Complex Generics And Hybrids

The US FDA and EMA have announced a pilot program to provide parallel scientific advice on complex generics and hybrid medicines for prospective applicants, with a goal of harmonization and increased regulatory convergence.

Regulation Europe

Shortlist Revealed For GGB Awards

Finalists across all 14 categories of the Global Generics & Biosimilars Awards 2021 have been revealed ahead of the awards ceremony on 10 November, following record entries this year.

Generic Drugs Biosimilars

BioFactura’s Ustekinumab Biosimilar To Be Trialed As ‘Robotic’ Pill

BioFactura, which is already using its ‘StableFast’ technology platform to develop its biosimilar ustekinumab candidate, has allied with fellow US-based biotech Rani Therapeutics to see if the biologic can be formulated into Rani’s proprietary ‘robotic’ pill.

Biosimilars Value-Added Medicines

Intas And Arecor Ally On Value-Added Development

Intas and Arecor have struck an exclusive licensing deal that will see the pair use Arecor’s proprietary Arestat formulation technology to develop value-added medicines, in particular for use outside of the hospital setting.

Deals Value-Added Medicines

Neuraxpharm and Panaxia Partner For Poland, After Germany And France

CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.

 

Europe Poland

Xellia CEO Questions Key Ingredients Reliance Of US And Europe

In an exclusive interview with Generics Bulletin, the CEO of API and FDF manufacturer Xellia Pharmaceuticals, expresses concern over supply chain resilience of the US and the EU, as he points out the weaknesses exposed by the pandemic. The company has also announced the release of its first anti-infectives manufactured at its newly operational Cleveland site. 

Generic Drugs Manufacturing

Dr Reddy’s Sells North American Rights For Celecoxib Oral Solution

India’s Dr Reddy’s has sold the US and Canadian rights to its 25mg/ml Elyxyb (celecoxib) oral solution to US-based BioDelivery Sciences International, for an upfront payment of $6m, followed by $9m within one year from closing the deal.

Canada United States

Generics Bulletin’s Top 50 Ranking For 2021

This article brings you a compilation of all the data from Generics Bulletin’s recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.

Generics Bulletin Top 50 Sales & Earnings

Biosimilars Players Climb Global Rankings

Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.

Generics Bulletin Top 50 Sales & Earnings
See All
UsernamePublicRestriction

Register